Scarica l'app Stockscreener
127.27
0.41%
-0.53
Pre-mercato:
127.13
-0.14
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$127.80
Aprire:
$127.8
Volume 24 ore:
3.43M
Relative Volume:
0.91
Capitalizzazione di mercato:
$26.90B
Reddito:
$398.11M
Utile/perdita netta:
$-1.03B
Rapporto P/E:
-22.37
EPS:
-5.69
Flusso di cassa netto:
$-868.57M
1 W Prestazione:
+12.74%
1M Prestazione:
+24.10%
6M Prestazione:
+56.43%
1 anno Prestazione:
+67.02%
Intervallo 1D:
$127.12
$130.13
Intervallo di 1 settimana:
$112.48
$130.13
Portata 52W:
$60.40
$130.13
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
127.27 | 27.01B | 398.11M | -1.03B | -868.57M | -5.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
What to do if you’re stuck in Insmed Incorporated2025 Stock Rankings & Weekly High Return Stock Opportunities - Newser
Is This a Bottoming Phase for Insmed Incorporated2025 Analyst Calls & Smart Money Movement Tracker - kangso.co.kr
Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market - uk.finance.yahoo.com
Non-Cystic Fibrosis Bronchiectasis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring - Barchart.com
Insmed announces FDA approval of Brinsupri for NCFB - MSN
Is Insmed Incorporated stock entering bullish territoryTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
Insmed's Brinsupri: A Game-Changer in the $3.7B Bronchiectasis Market and a Catalyst for Shareholder Value - AInvest
Insmed: What The Approval Of Brinsupri Will Change? - Seeking Alpha
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Is Insmed Incorporated stock forming a cup and handleWeekly Volume Report & Weekly Setup with High ROI Potential - thegnnews.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $173 - 富途牛牛
Insmed Director Makes a Major Move with Stock Sale! - TipRanks
Insmed's Stock Jumps 3.97% on FDA Approval, Hits $590M Top 500 Daily Volume - AInvest
Insmed Stock Surges 8.07% As Bullish Candlestick Pattern Signals Uptrend Continuation - AInvest
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic - MSN
Stifel Raises Price Target for Insmed to $145 - AInvest
Insmed Stock Soars: What’s Next? - StocksToTrade
Truist Securities maintains Buy rating on Insmed with PT raised to $139. - AInvest
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Truist Securities raises Insmed stock price target to $139 on brensocatib pricing - Investing.com Canada
Insmed price target raised to $145 from $121 at Stifel - TipRanks
Insmed price target raised to $139 from $126 at Truist - TipRanks
Insmed downgraded to Equal Weight from Overweight at Morgan Stanley - MSN
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $240 - 富途牛牛
Insmed stock price target raised to $240 from $120 at H.C. Wainwright - Investing.com Canada
Published on: 2025-08-14 16:09:54 - beatles.ru
Insmed stock price target raised to $173 from $109 at Wolfe Research - Investing.com Canada
Insmed Incorporated shares rise 3.37% premarket after multiple price target adjustments from UBS, RBC Capital, Mizuho, and Morgan Stanley. - AInvest
Insmed Incorporated May Be Forming Higher Low — Chartwatchers AlertJuly 2025 Breakouts & Real-Time Buy Signal Notifications - 선데이타임즈
Insmed Rises 0.71% as Volume Ranks 224th Post-FDA Approval Price Target Hiked to 240 - AInvest
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - MSN
Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating - AInvest
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - MSN
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Eastern Progress
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Goldman Sachs Raises Insmed Buy Rating to $142, PT from $114 - AInvest
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - Yahoo Finance
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 from $130 at Wells Fargo - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM Stock News - GuruFocus
Insmed gets first FDA approval for bronchiectasis - pharmaphorum
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):